Zhifei and GSK reached strategic cooperation, adding a new blockbuster product2023-10-12

On October 8, 2023, Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as "Zhifei") and GlaxoSmithKline (GSK Biologica...

Zhifei - Beijing R&D center expands to build innovative product incubation center2023-03-28

Based on the original technology platform of the R&D center in Beijing, Zhifei once again expands its R&D layout and builds an innovative p...

MSD and Zhifei Renew Collaboration on Vaccines2023-03-02

On January 21, 2023, through friendly negotiations between the two parties, Zhifei and MSD renewed the agreement on Supply, Distribution and...

Zhifei Longcom Recombinant COVID-19 Vaccine Receives Conditional Marketing Approval in Belarus2023-01-04

On January 3, local time, Zhifei longcom Recombinant COVID-19 Vaccine (CHO Cell) was approved for Conditional Marketing Approval by the Min...

Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approval in Kenya2022-12-23

On December 22, the Company's Recombinant COVID-19 Vaccine (CHO Cell) was approved for marketing by the Pharmacy and Poisons Board (PPB) of...